Diederik Gommers, MD, PhD, of Erasmus University in Rotterdam, the Netherlands, comments on the findings of a trial reporting no difference in 28-day mortality among patients with septic shock and high endotoxin activity randomized to polymyxin B hemoperfusion treatment plus conventional medical therapy vs sham treatment plus conventional medical therapy. Comments were made at the European Society of Intensive Care Medicine (ESICM) 31st Annual Congress, LIVES 2018, on October 24 in Paris. Used with permission.
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
You currently have no searches saved.
You currently have no courses saved.